-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 17th, Kite, a subsidiary of Gilead Sciences, and Shoreline Biosciences announced the establishment of a strategic partnership to develop new cell therapies that span multiple targets for hematological malignancies
This collaboration will combine Shoreline's deep expertise in induced pluripotent stem cell (iPSC) differentiation and gene reprogramming, and Kite's extensive cell therapy development technology, commercialization and production capabilities to jointly develop a series of innovations for the treatment of hematological malignancies Allogeneic (allogeneic) candidate therapy
Shoreline is committed to using smart technology to develop ready-to-use, standardized targeted cell therapies through iPSC, and has established a pipeline of candidate drugs for NK cell/macrophage therapy for the treatment of cancer and other serious diseases
▲Shoreline's iPSC-based cell therapy platform (picture source: Shoreline's official website)
Dr.
Reference materials:
[1] Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies.